Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-244X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial ; volume:19 ; number:1 ; day:29 ; month:11 ; year:2019 ; pages:1-9 ; date:12.2019
BMC psychiatry ; 19, Heft 1 (29.11.2019), 1-9, 12.2019
- Creator
-
Smith-Apeldoorn, Sanne Y.
Veraart, Jolien K. E.
Kamphuis, Jeanine
van Asselt, Antoinette D. I.
Touw, Daan J.
aan het Rot, Marije
Schoevers, Robert A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12888-019-2359-1
- URN
-
urn:nbn:de:101:1-2020051402125062767932
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Smith-Apeldoorn, Sanne Y.
- Veraart, Jolien K. E.
- Kamphuis, Jeanine
- van Asselt, Antoinette D. I.
- Touw, Daan J.
- aan het Rot, Marije
- Schoevers, Robert A.
- SpringerLink (Online service)
Other Objects (12)
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Personalized use of ketamine and esketamine for treatment-resistant depression
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Treatment-resistant depression: molecular mechanisms and management
Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Personalized use of ketamine and esketamine for treatment-resistant depression
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Treatment-resistant depression: molecular mechanisms and management
Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Personalized use of ketamine and esketamine for treatment-resistant depression
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Treatment-resistant depression: molecular mechanisms and management